Study #2020-0689
A Phase I, Open-Label Dose Escalation and Dose Expansion Study ofIntravenous GFH009 Single Agent in Patients with Relapsed/ Refractory Hematologic Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
GFH009
Description
GFH009 is a potent and highly selective CDK9 inhibitor. The study consists of a dose escalation and a dose expansion part. The purpose of this study is to investigate the safety and tolerability of GFH009 in relapsed/refractory hematologic malignancies [acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma], will also explore the preliminary anti-tumor activities of GFH009 in the studied population.
Information and next steps
Disease:
Hematologic Malignancies
Study phase:
I
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.